![]() |
Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
|
![]() |
|
![]() |
Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers
The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028 |
![]() |
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial
ENDO 2015 Annual Meeting |
![]() |
Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia
mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience |
![]() |
Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy
|
![]() |
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats
Diabetes, 60:1590–1598, May 2011 |
![]() |
Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular Permeability
Hypertension, February 2009; 53:175-181 |